ASX-listed biotech Cynata Therapeutics (ASX: CYP) is developing a portfolio of therapeutic products using its mesenchymal stem cells (MSCs) to potentially treat a wide array of diseases including graft-versus-host-disease, osteoarthritis, critical limb ischemia and cancer.
A number of patent applications have been filed by Cynata in the US, Europe, Australia and Japan to protect both its method of manufacturing MSCs at scale, using its CymerusTM platform, and the specific therapeutic products it is developing.
These company-owned patents are in addition to those based on technology developed at the University of Wisconsin-Madison (UWM) and at Cellular Dynamics International (CDI, now called Fujifilm CDI) and licenced to Cynata.
The Cymerus platform enables manufacture of mesenchymal stem cell (MSC) based products. Cymerus utilises induced pluripotent stem cells (iPSCs) as the starting material to manufacture its MSCs.
iPSCs have infinite expansion capacity and this creates Cyanta’s competitive advantage – the Cymerus platform is able manufacture MSCs at a commercial scale, without having to rely on a constant source of donors. This also ensures consistency of the stem cell products, an indispensable requirement of any marketed medicine.
Last year, the company was awarded a patent in the United States from the US Patent and Trademark Office (USPTO) covering aspects of its Cymerus™ platform.
This year, Cynata will be undertaking three phase 2 clinical trials and as they progress, and the company advances towards commercialisation, it has sought to ensure its intellectual property is well protected.
An Australian patent is expected to be granted by late April 2019 and will last for nearly 15 years – until March 2034.
Having received a Notice of Acceptance from IP Australia on January 7, it is fairly certain that the patent will soon be granted as such a document is normally received when IP Australia intends to grant the patent.
Two months earlier, Cynata previously received a similar notice (a ‘Notice of Allowance’) from the European Patent office. The ultimate approval is expected shortly, and it will carry the same 15-year term.
Cynata has also filed a number of patent protections in relation to the use of its stem cells in the treatment of adverse reactions associated with immunotherapies such as chimeric antigen receptor T-cell (CAR-T) products.
The granting of these patents forms an important part of the company’s strategy to build a strong portfolio of intellectual property.
In Australia, patents for stem cell therapeutics require an intervention with the biological materials and a demonstrable use. The latter criteria being proven by the company to a government body is vindication of its technology.
Cynata’s CEO Dr Ross Macdonald welcomed the granting of this patent, noting it provided further intellectual property protection for Cynata’s unique stem cell technology.
“This further patent reinforces our proprietary method of manufacturing MSCs which enables us to economically produce therapeutic MSCs at scale with consistent quality from a single blood donation”, he said.
“We look forward to the continued development of our patent estate as the Company also advances multiple Phase 2 clinical programs in multiple therapeutic areas of high unmet medical need during the course of 2019”.
This content is produced by Star Investing in commercial partnership with Cynata Therapeutics. This content does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Don’t miss a thing, subscribe now